Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 26,105 Shares of Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 26,105 shares of Clene stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $4.89, for a total value of $127,653.45. Following the completion of the sale, the insider owned 682,482 shares in the company, valued at approximately $3,337,336.98. The trade was a 3.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Thursday, January 15th, Chidozie Ugwumba sold 12,563 shares of Clene stock. The shares were sold at an average price of $5.10, for a total value of $64,071.30.
• On Wednesday, January 14th, Chidozie Ugwumba sold 19,621 shares of Clene stock. The stock was sold at an average price of $5.12, for a total value of $100,459.52.
• On Monday, January 12th, Chidozie Ugwumba sold 32,705 shares of Clene stock. The stock was sold at an average price of $5.50, for a total value of $179,877.50.
• On Friday, January 9th, Chidozie Ugwumba sold 9,075 shares of Clene stock. The shares were sold at an average price of $6.27, for a total value of $56,900.25.
• On Thursday, January 8th, Chidozie Ugwumba sold 3,195 shares of Clene stock. The shares were sold at an average price of $6.09, for a total value of $19,457.55.
• On Wednesday, January 7th, Chidozie Ugwumba sold 3,938 shares of Clene stock. The stock was sold at an average price of $6.29, for a total transaction of $24,770.02.
• On Tuesday, January 6th, Chidozie Ugwumba sold 3,111 shares of Clene stock. The stock was sold at an average price of $6.04, for a total transaction of $18,790.44.
• On Monday, January 5th, Chidozie Ugwumba sold 5,869 shares of Clene stock. The shares were sold at an average price of $5.87, for a total transaction of $34,451.03.
• On Friday, January 2nd, Chidozie Ugwumba sold 4,015 shares of Clene stock. The stock was sold at an average price of $5.73, for a total transaction of $23,005.95.
• On Wednesday, December 31st, Chidozie Ugwumba sold 13,095 shares of Clene stock. The stock was sold at an average price of $5.81, for a total transaction of $76,081.95.

Clene Trading Down 1.2%

Shares of NASDAQ CLNN opened at $5.05 on Friday. The stock has a market cap of $54.79 million, a PE ratio of -1.49 and a beta of 0.87. Clene Inc. has a 12-month low of $2.28 and a 12-month high of $13.50. The company has a 50-day moving average of $7.14 and a 200 day moving average of $6.45.

Clene (NASDAQ:CLNN) last released its earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.25). The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. On average, sell-side analysts forecast that Clene Inc. will post -5.19 EPS for the current fiscal year.

Institutional Investors Weigh In On Clene

A number of institutional investors have recently made changes to their positions in CLNN. Jones Financial Companies Lllp acquired a new position in shares of Clene in the 3rd quarter worth approximately $29,000. Jane Street Group LLC purchased a new stake in Clene in the second quarter valued at approximately $47,000. Lunt Capital Management Inc. lifted its stake in Clene by 71.2% during the second quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock worth $199,000 after purchasing an additional 21,217 shares in the last quarter. Finally, Scoggin Management LP boosted its position in shares of Clene by 42.8% during the second quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock worth $558,000 after buying an additional 42,750 shares during the period. 23.28% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CLNN has been the subject of several analyst reports. D. Boral Capital restated a “buy” rating and issued a $23.00 target price on shares of Clene in a report on Friday, January 9th. UBS Group reissued a “buy” rating on shares of Clene in a research report on Wednesday, December 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Clene in a research report on Friday, January 9th. Finally, Benchmark reiterated a “buy” rating on shares of Clene in a report on Thursday, December 4th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $32.60.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).